SG10201913485QA - Chimeric antigen receptors based on single-domain antibodies and methods of use thereof - Google Patents
Chimeric antigen receptors based on single-domain antibodies and methods of use thereofInfo
- Publication number
- SG10201913485QA SG10201913485QA SG10201913485QA SG10201913485QA SG10201913485QA SG 10201913485Q A SG10201913485Q A SG 10201913485QA SG 10201913485Q A SG10201913485Q A SG 10201913485QA SG 10201913485Q A SG10201913485Q A SG 10201913485QA SG 10201913485Q A SG10201913485Q A SG 10201913485QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- chimeric antigen
- domain antibodies
- antigen receptors
- receptors based
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464426—CD38 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510490002 | 2015-08-11 | ||
CN201510733585.2A CN105384825B (en) | 2015-08-11 | 2015-11-02 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913485QA true SG10201913485QA (en) | 2020-02-27 |
Family
ID=55417644
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913485QA SG10201913485QA (en) | 2015-08-11 | 2016-08-10 | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof |
SG11201900635QA SG11201900635QA (en) | 2015-08-11 | 2017-08-10 | Chimeric antigen receptors targeting bcma and methods of use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201900635QA SG11201900635QA (en) | 2015-08-11 | 2017-08-10 | Chimeric antigen receptors targeting bcma and methods of use thereof |
Country Status (30)
Country | Link |
---|---|
US (5) | US10934363B2 (en) |
EP (6) | EP4063397A1 (en) |
JP (7) | JP6859347B2 (en) |
KR (5) | KR20180035918A (en) |
CN (8) | CN105384825B (en) |
AU (5) | AU2016305075B2 (en) |
BR (2) | BR112018002844A2 (en) |
CA (3) | CA2994579C (en) |
CL (4) | CL2018000378A1 (en) |
CO (2) | CO2018001405A2 (en) |
CR (4) | CR20180153A (en) |
DK (1) | DK3896091T3 (en) |
EA (2) | EA201890302A1 (en) |
FI (1) | FI3896091T3 (en) |
HR (1) | HRP20231542T1 (en) |
HU (1) | HUE064534T2 (en) |
IL (3) | IL257297B (en) |
LT (1) | LT3896091T (en) |
MX (3) | MX2018001739A (en) |
MY (2) | MY188362A (en) |
NZ (1) | NZ750366A (en) |
PH (2) | PH12018500295A1 (en) |
PT (1) | PT3896091T (en) |
RS (1) | RS64925B1 (en) |
SA (1) | SA518390904B1 (en) |
SG (2) | SG10201913485QA (en) |
SI (1) | SI3896091T1 (en) |
UA (2) | UA125818C2 (en) |
WO (2) | WO2017025038A1 (en) |
ZA (2) | ZA201800703B (en) |
Families Citing this family (295)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9950282B2 (en) | 2012-03-15 | 2018-04-24 | Flodesign Sonics, Inc. | Electronic configuration and control for acoustic standing wave generation |
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
US9458450B2 (en) | 2012-03-15 | 2016-10-04 | Flodesign Sonics, Inc. | Acoustophoretic separation technology using multi-dimensional standing waves |
US10967298B2 (en) | 2012-03-15 | 2021-04-06 | Flodesign Sonics, Inc. | Driver and control for variable impedence load |
CN105939767B (en) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | Sound electrophoretic apparatus with alliteration electrophoresis chamber |
CN104004095B (en) * | 2014-06-04 | 2016-11-23 | 博生吉医药科技(苏州)有限公司 | A kind of CD7 nano antibody, its coded sequence and application |
US11021699B2 (en) | 2015-04-29 | 2021-06-01 | FioDesign Sonics, Inc. | Separation using angled acoustic waves |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
SG10201913682QA (en) * | 2015-06-25 | 2020-03-30 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
US11474085B2 (en) | 2015-07-28 | 2022-10-18 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
US11459540B2 (en) | 2015-07-28 | 2022-10-04 | Flodesign Sonics, Inc. | Expanded bed affinity selection |
CN105384825B (en) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
EP3402825A1 (en) | 2016-01-12 | 2018-11-21 | Crescendo Biologics Limited | Molecules that bind prostate specific membrane antigen (psma) |
CN108778329B (en) | 2016-02-17 | 2022-09-16 | 西雅图基因公司 | BCMA antibodies and their use to treat cancer and immune disorders |
CN110699371A (en) * | 2016-03-18 | 2020-01-17 | 江苏普瑞康生物医药科技有限公司 | Fc gamma RIIa-based chimeric gene and application thereof |
CN109414455B (en) | 2016-04-01 | 2023-01-20 | 凯德药业股份有限公司 | BCMA binding molecules and methods of use thereof |
SI3436079T1 (en) * | 2016-04-01 | 2022-01-31 | Kite Pharma, Inc. | Chimeric antigen and t cell receptors and methods of use |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US11085035B2 (en) | 2016-05-03 | 2021-08-10 | Flodesign Sonics, Inc. | Therapeutic cell washing, concentration, and separation utilizing acoustophoresis |
GB201607968D0 (en) * | 2016-05-06 | 2016-06-22 | Crescendo Biolog Ltd | Chimeric antigen receptor |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
AU2017281034B2 (en) | 2016-06-21 | 2024-03-14 | Teneobio, Inc. | CD3 binding antibodies |
EP3484927A1 (en) * | 2016-07-15 | 2019-05-22 | Poseida Therapeutics, Inc. | Chimeric antigen receptors (cars) specific for muc1 and methods for their use |
WO2018052503A1 (en) | 2016-09-14 | 2018-03-22 | Teneobio, Inc. | Cd3 binding antibodies |
WO2018058432A1 (en) * | 2016-09-28 | 2018-04-05 | 李华顺 | Polygenic recombinant chimeric antigen receptor molecule and use thereof |
WO2018068201A1 (en) * | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
EP3529347A1 (en) | 2016-10-19 | 2019-08-28 | Flodesign Sonics, Inc. | Affinity cell extraction by acoustics |
CN106755108A (en) * | 2016-12-05 | 2017-05-31 | 刘晓明 | A kind of slow virus carrier of expression CD19 and CD20 antibody gene Chimeric antigen receptors and preparation method thereof |
CN106701827A (en) * | 2016-12-05 | 2017-05-24 | 刘晓明 | Transformation, multiplication culture and preservation method for T cell for expressing CD19 and CD20 antibody gene CAR (chimeric antigen receptor) |
CN106755109A (en) * | 2016-12-05 | 2017-05-31 | 刘晓明 | A kind of slow virus carrier for expressing people's CD19 and CD20 Chimeric antigen receptor gene |
MX2019006598A (en) | 2016-12-09 | 2019-10-15 | Onkimmune Ltd | Engineered natural killer cells and uses thereof. |
CN106822184A (en) * | 2016-12-15 | 2017-06-13 | 梁爱斌 | The united CAR T cells preparation of Mutiple Targets and preparation method |
EP4215548A1 (en) | 2016-12-21 | 2023-07-26 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
CN108276493B (en) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | Chimeric antigen receptor and application thereof |
CN106749677B (en) * | 2017-01-04 | 2020-06-12 | 上海交通大学医学院附属瑞金医院 | Bispecific chimeric antigen receptor gene targeting MLL leukemia and application thereof |
WO2018127710A1 (en) | 2017-01-06 | 2018-07-12 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
EP3577134A1 (en) | 2017-01-31 | 2019-12-11 | Novartis AG | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
CN108395482B (en) | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | Construction of targeting CD20 antigen chimeric antigen receptor and activity identification of engineered T cell thereof |
CA3052779A1 (en) | 2017-02-17 | 2018-08-23 | Fred Hutchinson Cancer Research Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
EP3619235A1 (en) | 2017-04-11 | 2020-03-11 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
CN108728465A (en) * | 2017-04-14 | 2018-11-02 | 深圳新诺微环生物科技有限公司 | A kind of minicircle dna carrier and its preparation method and application of expression target cell-effector cell's bridge |
CA3059753A1 (en) * | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Chimeric antibody/t-cell receptor constructs and uses thereof |
WO2018201056A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018201051A1 (en) | 2017-04-28 | 2018-11-01 | Novartis Ag | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
CA3061945A1 (en) | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
KR102376863B1 (en) | 2017-05-12 | 2022-03-21 | 하푼 테라퓨틱스, 인크. | mesothelin binding protein |
CN107299110B (en) * | 2017-05-27 | 2019-11-22 | 上海优卡迪生物医药科技有限公司 | A kind of cancer of pancreas based on OCTS technology, malignant mesothelioma CAR-T therapy vector and its construction method and application |
CN107245500B (en) * | 2017-05-27 | 2019-05-17 | 上海优卡迪生物医药科技有限公司 | A kind of leaching based on OCTS technology is leukaemia CAR-T therapy vector and its construction method and application |
CN107337736B (en) * | 2017-06-06 | 2019-07-26 | 上海优卡迪生物医药科技有限公司 | The bis- targeting Chimeric antigen receptors of OCTS-CAR, encoding gene, recombinant expression carrier and its building and application |
EP3638218A4 (en) | 2017-06-14 | 2021-06-09 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
WO2018237037A2 (en) * | 2017-06-20 | 2018-12-27 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
AU2018288803A1 (en) * | 2017-06-20 | 2020-02-06 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
WO2019000223A1 (en) * | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | Chimeric antibody immune effctor cell engagers and methods of use thereof |
JP7288405B2 (en) * | 2017-06-30 | 2023-06-07 | アメリカ合衆国 | Anti-B cell maturation antigen chimeric antigen receptor with human domain |
GB201711068D0 (en) | 2017-07-10 | 2017-08-23 | Crescendo Biologics Ltd | Therapeutic molecules binding PSMA |
CN109232742B (en) * | 2017-07-11 | 2021-10-22 | 深圳市第二人民医院 | Chimeric antigen receptor and application thereof |
WO2019014891A1 (en) * | 2017-07-20 | 2019-01-24 | 深圳普瑞金生物药业有限公司 | Egfr single-domain antibody cart for treating tumor and application thereof |
US20200165348A1 (en) * | 2017-07-20 | 2020-05-28 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Cd123-binding chimeric antigen receptors |
AU2018309735A1 (en) | 2017-07-31 | 2020-02-20 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy |
EP3675897A1 (en) * | 2017-09-01 | 2020-07-08 | Dana Farber Cancer Institute, Inc. | Immunogenic peptides specific to bcma and taci antigens for treatment of cancer |
CA3075399A1 (en) * | 2017-09-13 | 2019-03-21 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
US11447559B2 (en) | 2017-09-29 | 2022-09-20 | Mogam Institute For Biomedical Research | Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same |
CR20200195A (en) * | 2017-10-13 | 2020-08-14 | Harpoon Therapeutics Inc | B cell maturation antigen binding proteins |
KR102569133B1 (en) * | 2017-10-13 | 2023-08-21 | 하푼 테라퓨틱스, 인크. | Trispecific proteins and methods of use |
TWI829655B (en) | 2017-10-18 | 2024-01-21 | 瑞士商諾華公司 | Compositions and methods for selective protein degradation |
KR20200116077A (en) | 2017-11-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | Chimeric antigen receptor and coding polynucleotide specific for B cell maturation antigen |
WO2019090364A1 (en) | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
JP2021502979A (en) | 2017-11-15 | 2021-02-04 | ノバルティス アーゲー | BCMA targeting chimeric antigen receptor, CD19 targeting chimeric antigen receptor and combination therapy |
KR20200096253A (en) | 2017-11-30 | 2020-08-11 | 노파르티스 아게 | BCMA-targeting chimeric antigen receptor, and uses thereof |
AU2018385759B2 (en) | 2017-12-14 | 2021-10-21 | Flodesign Sonics, Inc. | Acoustic transducer driver and controller |
WO2019126724A1 (en) * | 2017-12-22 | 2019-06-27 | Bluebird Bio, Inc. | Multivalent chimeric antigen receptor |
CN109970860A (en) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | Three chain antibodies, Its Preparation Method And Use |
CN109971715A (en) * | 2017-12-28 | 2019-07-05 | 深圳华大生命科学研究院 | A kind of cultural method of specific amplification CAR-T cell |
WO2019127215A1 (en) * | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof |
CN109988242A (en) * | 2018-01-02 | 2019-07-09 | 武汉波睿达生物科技有限公司 | Joint Chimeric antigen receptor, expression vector, slow virus and T cell |
CN112218651A (en) | 2018-01-08 | 2021-01-12 | 诺华公司 | Immunopotentiating RNA for combination with chimeric antigen receptor therapy |
CN108285486A (en) * | 2018-01-15 | 2018-07-17 | 浙江阿思科力生物科技有限公司 | Using CD20 as the specific antibody of target spot, CAR-NK cells and its preparation and application |
KR102115236B1 (en) * | 2018-01-29 | 2020-05-27 | (주)에스엠티바이오 | Chimera antigen receptors for treating pancreatic cancer or biliary tract cancer |
CN108341881B (en) * | 2018-01-31 | 2020-08-18 | 深圳市默赛尔生物医学科技发展有限公司 | Chimeric antigen receptor with safety switch, expression gene thereof, NK cell modified by chimeric antigen receptor and application of chimeric antigen receptor |
US20210038659A1 (en) | 2018-01-31 | 2021-02-11 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
CN108314739B (en) * | 2018-02-05 | 2020-07-14 | 深圳市默赛尔生物医学科技发展有限公司 | Multi-signal chimeric antigen receptor, expression gene thereof, NK cell modified by multi-signal chimeric antigen receptor and application of NK cell |
CN110129369B (en) * | 2018-02-09 | 2023-10-13 | 上海交通大学医学院附属上海儿童医学中心 | Chimeric antigen receptor gene engineering vector, immune cell and application thereof |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
CN112119099A (en) | 2018-03-02 | 2020-12-22 | Cdr-生物科技股份有限公司 | Trispecific antigen binding proteins |
CN108220247A (en) * | 2018-03-20 | 2018-06-29 | 杭州史迪姆生物科技有限公司 | A kind of double CAR-T cells and its preparation method and application |
EP3549597A1 (en) * | 2018-04-06 | 2019-10-09 | Heinrich-Heine-Universität Düsseldorf | Synthetic signalling constructs and its use |
WO2019195586A1 (en) * | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating egfrviii expressing glioblastomas |
CN110372796B (en) * | 2018-04-12 | 2023-05-02 | 上海赛比曼生物科技有限公司 | Chimeric antigen receptor targeting BCMA and preparation method and application thereof |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
KR20210011002A (en) * | 2018-05-16 | 2021-01-29 | 얀센 바이오테크 인코포레이티드 | Methods of treating cancer and methods of improving the efficacy of T-cell reinduction therapeutics |
US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
CN110606893B (en) * | 2018-06-15 | 2022-11-15 | 北昊干细胞与再生医学研究院有限公司 | Method for treating tumor by chimeric antigen receptor T cell targeting CD19 and CD20 double antigens |
CN116769032A (en) * | 2018-07-20 | 2023-09-19 | 坦尼奥第二公司 | Heavy chain antibodies that bind CD19 |
AU2019318135A1 (en) * | 2018-08-10 | 2021-03-04 | Sangamo Therapeutics France | New car constructs comprising TNFR2 domains |
GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
CN109134665B (en) * | 2018-08-24 | 2021-06-11 | 上海先博生物科技有限公司 | BCMA chimeric antigen receptor based on single domain antibody and application |
CN111542343B (en) * | 2018-08-24 | 2023-08-18 | 上海先博生物科技有限公司 | anti-BCMA single domain antibodies and uses thereof |
WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP3844267A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
EP3850013A4 (en) * | 2018-09-10 | 2022-10-05 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against cll1 and constructs thereof |
CN109293781A (en) * | 2018-09-12 | 2019-02-01 | 中国人民解放军总医院 | The T cell and its application of Chimeric antigen receptor and its gene and recombinant expression carrier, the bis- targetings of CD19-CD20 |
CN109081870B (en) * | 2018-09-21 | 2021-12-03 | 成都阿帕克生物科技有限公司 | Nano antibody of anti-human chorionic gonadotropin beta subunit, nucleic acid molecule and application |
CN109265550B (en) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | BCMA antibodies, chimeric antigen receptors and drugs |
JP7425049B2 (en) | 2018-09-25 | 2024-01-30 | ハープーン セラピューティクス,インク. | DLL3 binding protein and method of use |
WO2020061796A1 (en) * | 2018-09-26 | 2020-04-02 | Hrain Biotechnology Co., Ltd. | Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
CN109503716B (en) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | Bispecific chimeric antigen receptor molecule and application thereof in tumor treatment |
EP3864045A2 (en) * | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
CN112955467A (en) * | 2018-10-26 | 2021-06-11 | 特尼奥生物股份有限公司 | Heavy chain antibodies that bind to CD38 |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
WO2020092854A2 (en) | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d) |
CN109504660B (en) * | 2018-11-02 | 2021-08-06 | 温州启星生物技术有限公司 | Fourth-generation CAR-T cell and construction method and application thereof |
AU2019377854A1 (en) | 2018-11-08 | 2021-05-27 | Juno Therapeutics, Inc. | Methods and combinations for treatment and T cell modulation |
CN109468283A (en) * | 2018-11-30 | 2019-03-15 | 北京美康基免生物科技有限公司 | A kind of immunocyte of the dual Chimeric antigen receptor gene modification based on CD19 and BCMA and its application |
CN110951689A (en) * | 2018-11-30 | 2020-04-03 | 北京美康基免生物科技有限公司 | CD19 and CD30 based double chimeric antigen receptor gene modified immune cell and application thereof |
BR112021012172A2 (en) * | 2018-12-12 | 2021-08-31 | Kite Pharma, Inc. | CHIMERIC AND T-CELL ANTIGEN RECEPTORS AND METHODS OF USE |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
CN109485732B (en) * | 2018-12-20 | 2021-09-24 | 四川大学华西医院 | Genetically modified double-target chimeric antigen receptor and application thereof |
CN109651511B (en) * | 2018-12-26 | 2020-06-09 | 广州百暨基因科技有限公司 | BCMA (brain cell activating antigen) targeted chimeric antigen receptor and application thereof |
CN109652379B (en) * | 2018-12-29 | 2022-08-16 | 博生吉医药科技(苏州)有限公司 | CD7 chimeric antigen receptor modified NK-92MI cell and application thereof |
CN109485734B (en) * | 2018-12-30 | 2020-05-12 | 广州百暨基因科技有限公司 | Bispecific chimeric antigen receptor targeting BCMA and CD19 and application thereof |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
JP2022524178A (en) * | 2019-01-07 | 2022-04-28 | セルリス パルティシパソエス リミターダ | How to Modulate Tumor Microenvironment with Bispecificity in Tandem Receptor CAR |
CN109678961A (en) * | 2019-01-15 | 2019-04-26 | 深圳市南科生物工程有限公司 | A kind of construction method of the Chimeric antigen receptor based on BMCA nano antibody sequence and its application |
CN113330038A (en) * | 2019-01-22 | 2021-08-31 | 亘喜生物科技(上海)有限公司 | CD20 combination targeted engineered immune cells |
CA3125033A1 (en) | 2019-01-22 | 2020-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
WO2020163325A1 (en) * | 2019-02-04 | 2020-08-13 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
CN109734814A (en) * | 2019-02-12 | 2019-05-10 | 南京卡提医学科技有限公司 | The purposes of engineering T cell treating cancer with immunity receptor |
EP3930763A1 (en) | 2019-02-25 | 2022-01-05 | Novartis AG | Mesoporous silica particles compositions for viral delivery |
US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
AU2020240132A1 (en) | 2019-03-21 | 2021-09-16 | Regeneron Pharmaceuticals, Inc. | Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy |
EP3953455A1 (en) | 2019-04-12 | 2022-02-16 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
CN109942709B (en) * | 2019-04-22 | 2019-12-27 | 广州百暨基因科技有限公司 | anti-BCMA single domain antibody and application thereof |
WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
EP3733707A1 (en) | 2019-04-30 | 2020-11-04 | Celyad S.A. | Car t-cells targeting bcma and uses thereof |
JP2022531765A (en) * | 2019-05-04 | 2022-07-11 | インヒブルクス インコーポレイテッド | CD33 binding polypeptide and its use |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
JP2022535410A (en) * | 2019-06-04 | 2022-08-08 | ザ ジェネラル ホスピタル コーポレイション | Antibodies and chimeric antigen receptors targeting TACI |
JP2022537931A (en) | 2019-06-14 | 2022-08-31 | テネオバイオ, インコーポレイテッド | A multispecific heavy chain antibody that binds to CD22 and CD3 |
MX2022000016A (en) * | 2019-06-27 | 2022-02-24 | Crispr Therapeutics Ag | Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer. |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
CN110540997B (en) * | 2019-08-29 | 2024-02-13 | 浙江煦顼技术有限公司 | BCMA chimeric antigen receptor, nucleic acid sequence, vector and application |
KR20220051002A (en) * | 2019-08-30 | 2022-04-25 | 얀센 바이오테크 인코포레이티드 | B-cell maturation complex CAR T construct and primers |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
WO2021043169A1 (en) * | 2019-09-02 | 2021-03-11 | 成都盛世君联生物技术有限公司 | Antibody that binds specifically to b-cell maturation antigen and use thereof |
WO2021054789A1 (en) * | 2019-09-18 | 2021-03-25 | 주식회사 에스엘바이젠 | Genetically modified nk cell line transduced with gene encoding novel chimeric antigen receptor and use thereof |
WO2021057866A1 (en) * | 2019-09-26 | 2021-04-01 | 苏州克睿基因生物科技有限公司 | Single domain antibody and chimeric antigen receptor comprising antibody structure |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
CA3155246A1 (en) * | 2019-10-21 | 2021-04-29 | Sandro MATOSEVIC | Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques |
EP4031250A1 (en) | 2019-10-22 | 2022-07-27 | The United States of America, as represented by the Secretary, Department of Health and Human Services | High affinity nanobodies targeting b7h3 (cd276) for treating multiple solid tumors |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
EP4055049A1 (en) | 2019-11-05 | 2022-09-14 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy of multiple myeloma |
EP4065158A2 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Chimeric antigen receptors binding bcma and cd19 and uses thereof |
EP4065606A4 (en) * | 2019-11-26 | 2023-08-02 | Ramot at Tel-Aviv University Ltd. | Chimeric antigen receptor to carbohydrate antigens |
BR112022011666A2 (en) * | 2019-12-16 | 2022-12-20 | Nanjing Legend Biotech Co Ltd | CHIMERIC ANTIGEN RECEPTOR, ISOLATED NUCLEIC ACID, VECTOR, IMMUNE CELL, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OF A DISEASE, ANTIBODY |
CN111171158B (en) * | 2020-01-17 | 2020-10-30 | 南京蓝盾生物科技有限公司 | Chimeric antigen receptor simultaneously targeting BCMA and CD38 and application thereof |
CN111235113A (en) * | 2020-01-21 | 2020-06-05 | 南京北恒生物科技有限公司 | Immune cells comprising chimeric antigen receptors and uses thereof |
US20230172982A1 (en) * | 2020-01-30 | 2023-06-08 | Immunitybio, Inc. | Elimination of BCMA-positive malignancies by CAR expressing NK cells |
CN111196858B (en) * | 2020-02-05 | 2021-02-09 | 武汉科技大学 | Bispecific chimeric antigen receptor for treating hematological tumor complicated with HIV infection, gene, construction method and application thereof |
EP4105240A1 (en) | 2020-02-13 | 2022-12-21 | Sichuan University | Chimeric antigen receptor and use thereof |
US20230183312A1 (en) * | 2020-02-14 | 2023-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors with cd2 activation |
CA3173394A1 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP4110377A2 (en) | 2020-02-27 | 2023-01-04 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
CN113402612A (en) * | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof |
KR20230009386A (en) | 2020-04-10 | 2023-01-17 | 주노 쎄러퓨티크스 인코퍼레이티드 | Methods and uses for cell therapy engineered with chimeric antigen receptors targeting B-cell maturation antigens |
EP4142723A2 (en) | 2020-04-28 | 2023-03-08 | Juno Therapeutics, Inc. | Combination of bcma-directed t cell therapy and an immunomodulatory compound |
BR112022021690A2 (en) | 2020-04-29 | 2022-12-20 | Teneobio Inc | MULTISPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS |
CN115777017A (en) * | 2020-05-06 | 2023-03-10 | 亘喜生物科技(上海)有限公司 | Compositions and methods for T cell engineering |
CN111574629B (en) * | 2020-06-01 | 2021-07-20 | 宁夏医科大学 | CD 20-resistant nano antibody, encoding gene, recombinant nano antibody, recombinant vector, recombinant strain and application |
CN111607565A (en) * | 2020-06-04 | 2020-09-01 | 河南大学 | In-vitro amplification method of T cells of northern Pingting monkeys |
EP4165169A1 (en) | 2020-06-11 | 2023-04-19 | Novartis AG | Zbtb32 inhibitors and uses thereof |
AU2021296423A1 (en) | 2020-06-22 | 2023-02-02 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy |
US20230242678A1 (en) * | 2020-06-26 | 2023-08-03 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
WO2022011531A1 (en) * | 2020-07-14 | 2022-01-20 | 浙江道尔生物科技有限公司 | Anti-cld18a2 single-domain antibody |
EP4182356A1 (en) * | 2020-07-16 | 2023-05-24 | Nanjing Legend Biotech Co., Ltd. | Multispecific chimeric antigen receptors and uses thereof |
CN111848798B (en) * | 2020-07-27 | 2022-05-13 | 源道隆(苏州)医学科技有限公司 | Nanometer antibody capable of combining BCMA and application thereof |
CN111909271B (en) * | 2020-08-12 | 2021-03-23 | 深圳市茵冠生物科技有限公司 | BCMA chimeric antigen receptor based on single domain antibody and application thereof |
CN116390946A (en) | 2020-08-13 | 2023-07-04 | 美国政府(由卫生和人类服务部的部长所代表) | IGG4 hinge-containing chimeric antigen receptor for the treatment of solid tumors targeting glypican-1 (GPC 1) |
WO2022037528A1 (en) | 2020-08-20 | 2022-02-24 | 正大天晴药业集团股份有限公司 | Single variable domain and antigen binding molecule binding bcma |
US20230193292A1 (en) | 2020-08-20 | 2023-06-22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bcma-binding single variable structural domain and antigen-binding molecule |
WO2022040586A2 (en) | 2020-08-21 | 2022-02-24 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
CN112062864A (en) * | 2020-09-18 | 2020-12-11 | 樊克兴 | Preparation method and application of targeting BCMA tumor antigen receptor modified T cells |
CN112251412B (en) * | 2020-10-12 | 2023-03-28 | 汤朝阳 | BCMA (brain cell activating antigen) targeted chimeric antigen receptor T cell and application thereof |
CN111925451B (en) * | 2020-10-12 | 2021-01-29 | 佑仁细胞工程(浙江)有限公司 | BCMA (brain cell activating antigen) -targeted Chimeric Antigen Receptor (CAR) and application thereof |
WO2022093745A1 (en) | 2020-10-26 | 2022-05-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting sars coronavirus spike protein and uses thereof |
CN112028996B (en) * | 2020-10-30 | 2021-01-22 | 南京北恒生物科技有限公司 | Single domain antibodies targeting BCMA and uses thereof |
WO2022098787A1 (en) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
WO2022116086A1 (en) * | 2020-12-03 | 2022-06-09 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
EP4272002A1 (en) | 2020-12-04 | 2023-11-08 | Celgene Corporation | Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors |
TW202237638A (en) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
TW202237639A (en) | 2020-12-09 | 2022-10-01 | 日商武田藥品工業股份有限公司 | Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof |
WO2022140388A1 (en) | 2020-12-21 | 2022-06-30 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
CN116390954A (en) * | 2020-12-29 | 2023-07-04 | 宁波茂行生物医药科技有限公司 | Single domain antibodies targeting BCMA |
EP4271404A2 (en) | 2020-12-31 | 2023-11-08 | Sana Biotechnology, Inc. | Methods and compositions for modulating car-t activity |
CN112321713B (en) * | 2020-12-31 | 2021-05-25 | 北京艺妙神州医药科技有限公司 | anti-BCMA antibody and application thereof |
KR20230151513A (en) | 2021-01-11 | 2023-11-01 | 사나 바이오테크놀로지, 인크. | Uses of CD8 Targeting Viral Vectors |
CN114149505B (en) * | 2021-01-12 | 2022-11-04 | 北京门罗生物科技有限公司 | Immune cell for treating B cell related diseases, preparation method and application thereof |
IL303853A (en) | 2021-01-29 | 2023-08-01 | Allogene Therapeutics Inc | KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS |
CN112778427B (en) * | 2021-01-29 | 2022-03-15 | 武汉思安医疗技术有限公司 | Bispecific CS1-BCMA CAR-T cells and uses thereof |
JP2024506200A (en) | 2021-02-15 | 2024-02-09 | 武田薬品工業株式会社 | Compositions for cell therapy and methods of modulating TGF-B signaling |
WO2022183160A1 (en) * | 2021-02-25 | 2022-09-01 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Methods for treating cd83-expressing cancer |
CN117693508A (en) | 2021-03-03 | 2024-03-12 | 朱诺治疗学股份有限公司 | Combination of T cell therapy and DGK inhibitors |
CN115109156B (en) * | 2021-03-22 | 2024-03-08 | 浙江纳米抗体技术中心有限公司 | BCMA-targeted nano antibody and application thereof |
CR20230474A (en) * | 2021-04-06 | 2023-11-23 | Teneobio Inc | Anti-cd19 antibodies and car-t structures |
WO2022221844A2 (en) * | 2021-04-13 | 2022-10-20 | WUGEN, Inc. | Improved chimeric antigen receptors and uses thereof |
BR112023020341A2 (en) | 2021-04-15 | 2024-02-06 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | MULTI-SPECIFIC ANTIBODY, PHARMACEUTICAL COMPOSITION, METHOD FOR TREATING A DISEASE RELATED TO BCMA EXPRESSION AND BCMA-BINDING ANTIBODY |
WO2022221737A1 (en) | 2021-04-16 | 2022-10-20 | Juno Therapeutics, Inc. | T cell therapy in patients who have had prior stem cell transplant |
KR20230171468A (en) | 2021-04-16 | 2023-12-20 | 셀진 코포레이션 | Combination therapy with BCMA-directed T cell therapy |
CN117337303A (en) * | 2021-04-16 | 2024-01-02 | 特尼奥生物股份有限公司 | anti-CD 20 antibodies and CAR-T structures |
TW202309294A (en) | 2021-04-27 | 2023-03-01 | 瑞士商諾華公司 | Viral vector production system |
WO2022232612A1 (en) | 2021-04-29 | 2022-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Lassa virus-specific nanobodies and methods of their use |
WO2022228579A1 (en) * | 2021-04-30 | 2022-11-03 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting gpc3 and methods of use thereof |
JP2024517863A (en) | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Methods for stimulating and transducing cells |
TW202309522A (en) | 2021-05-11 | 2023-03-01 | 美商健生生物科技公司 | Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma |
BR112023023269A2 (en) | 2021-05-11 | 2024-01-30 | Janssen Biotech Inc | METHODS OF MINIMIZING NEUROTOXICITY ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY |
BR112023024231A2 (en) | 2021-05-19 | 2024-01-30 | Sana Biotechnology Inc | HYPOIMMUNOGENIC RHD NEGATIVE PRIMARY T CELLS |
EP4341286A1 (en) * | 2021-05-19 | 2024-03-27 | Celledit LLC | Bi-specific chimeric antigen receptors and genetically engineered immune cells expressing such |
IL308097A (en) | 2021-05-27 | 2023-12-01 | Sana Biotechnology Inc | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
CA3216228A1 (en) | 2021-06-09 | 2022-12-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cross species single domain antibodies targeting pd-l1 for treating solid tumors |
AU2022301302A1 (en) | 2021-07-01 | 2024-01-25 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
AU2022309875A1 (en) | 2021-07-14 | 2024-01-25 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
WO2023288267A1 (en) | 2021-07-14 | 2023-01-19 | 2Seventy Bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
TW202321457A (en) | 2021-08-04 | 2023-06-01 | 美商薩那生物科技公司 | Use of cd4-targeted viral vectors |
CA3227613A1 (en) | 2021-08-11 | 2023-02-16 | William Dowdle | Inducible systems for altering gene expression in hypoimmunogenic cells |
AU2022326908A1 (en) * | 2021-08-12 | 2024-03-28 | Cellogen Therapeutics Pvt. Ltd. | Chimeric antigen receptors (car) for b cell malignancies |
CN113651893B (en) * | 2021-08-12 | 2023-08-01 | 上海生物制品研究所有限责任公司 | HER2 and MESO combined double-target CAR-T vector, construction method thereof and application thereof in cancers |
CA3229746A1 (en) | 2021-08-20 | 2023-02-23 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
US11359012B1 (en) | 2021-08-27 | 2022-06-14 | Nanjing Kaedi Biotherapeutics Ltd. | Specific chimeric antigen receptor cells targeting human CLDN18A2, preparation method and application thereof |
CN115894704B (en) * | 2021-09-24 | 2023-12-26 | 四川大学 | Antibody specifically targeting tumor EpCAM antigen and application thereof |
AU2022358512A1 (en) * | 2021-09-29 | 2024-04-18 | Modex Therapeutics, Inc. | Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof |
CA3234046A1 (en) * | 2021-10-07 | 2023-04-13 | Mehdi Arbabi-Ghahroudi | Anti-bcma single domain antibodies and therapeutic constructs |
WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
WO2023076881A1 (en) | 2021-10-26 | 2023-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein |
CN114015674A (en) | 2021-11-02 | 2022-02-08 | 辉二(上海)生物科技有限公司 | Novel CRISPR-Cas12i system |
WO2023079494A1 (en) | 2021-11-03 | 2023-05-11 | Janssen Biotech, Inc. | Corticosteriod reduction in treatment with anti-cd38 antibodies |
WO2023081735A1 (en) | 2021-11-03 | 2023-05-11 | Celgene Corporation | Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma |
WO2023081752A1 (en) | 2021-11-04 | 2023-05-11 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
WO2023077343A1 (en) | 2021-11-04 | 2023-05-11 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
WO2023086829A1 (en) | 2021-11-09 | 2023-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Igg4 hinge-containing chimeric antigen receptors targeting glypican-3 (gpc3) and use thereof |
CN115466331B (en) * | 2021-11-18 | 2023-05-30 | 合源生物科技(天津)有限公司 | Chimeric antigen receptor targeting BCMA and application thereof |
CN116284385A (en) * | 2021-12-07 | 2023-06-23 | 信达细胞制药(苏州)有限公司 | P329G antibody targeting BCMA and combination and application of P329G antibody and chimeric antigen receptor cell |
CN114195898B (en) * | 2021-12-13 | 2022-10-28 | 南京凯地医疗技术有限公司 | Humanized anti-CD 33 single-domain antibody and construct preparation method and application thereof |
WO2023109257A1 (en) * | 2021-12-16 | 2023-06-22 | 浙江瑞加美生物科技有限公司 | Humanized bcma antibody and bcma-car-t/bcma-car-dnt cell |
WO2023115039A2 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
TW202342757A (en) | 2021-12-17 | 2023-11-01 | 美商薩那生物科技公司 | Modified paramyxoviridae attachment glycoproteins |
WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
WO2023129819A2 (en) * | 2021-12-29 | 2023-07-06 | Rutgers, The State University Of New Jersey | Single-domain high affinity antibodies and methods of use thereof |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023158986A1 (en) | 2022-02-15 | 2023-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereof |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
WO2023164695A2 (en) | 2022-02-28 | 2023-08-31 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
CN114685664B (en) * | 2022-04-12 | 2023-10-20 | 内蒙古农业大学 | Single-domain antibody for resisting human B lymphocyte surface antigen CD20 and application thereof |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023217067A1 (en) * | 2022-05-09 | 2023-11-16 | 上海先博生物科技有限公司 | Engineered immune effector cell and use thereof in combination with cbl-b inhibitor |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
CN117279949A (en) * | 2022-05-27 | 2023-12-22 | 苏州易慕峰生物科技有限公司 | Chimeric antigen receptor comprising CLDN18.2 single domain antibody and uses thereof |
WO2023244547A1 (en) * | 2022-06-13 | 2023-12-21 | The Regents Of The University Of California | Humanized antibodies to human integrin avb8 |
US20240052049A1 (en) * | 2022-06-24 | 2024-02-15 | Orna Therapeutics, Inc. | Circular rna encoding chimeric antigen receptors targeting bcma |
CN114805582B (en) * | 2022-06-29 | 2022-10-04 | 上海恒润达生生物科技股份有限公司 | anti-Trop 2 nano antibody and application thereof |
WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024026445A1 (en) | 2022-07-29 | 2024-02-01 | Allogene Therapeutics Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
WO2024041650A1 (en) * | 2022-08-25 | 2024-02-29 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof |
WO2024050399A1 (en) | 2022-09-01 | 2024-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes |
CN116023495B (en) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | anti-CD40 nano antibody and preparation method and application thereof |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
CN115925947B (en) * | 2022-09-27 | 2023-08-22 | 上海百英生物科技股份有限公司 | Affinity maturation method and affinity maturation of anti-human PD-L1 single-domain antibody |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
CN116120465B (en) * | 2022-11-01 | 2023-10-13 | 邦恩泰(山东)生物医药科技集团股份有限公司 | Chimeric antigen receptor targeting BCMA and/or FCRH5 and application thereof |
CN117069844B (en) * | 2022-12-06 | 2024-02-09 | 成都赛恩吉诺生物科技有限公司 | Bispecific antibody containing specific isoelectric point anti-human BCMA nano antibody and application thereof |
CN117164712A (en) * | 2023-02-22 | 2023-12-05 | 成都优赛诺生物科技有限公司 | CD 22-targeted single domain antibody, chimeric antigen receptor and application thereof |
CN116640229B (en) * | 2023-04-10 | 2024-01-30 | 中国人民解放军总医院第五医学中心 | Construction and application of low-pH targeted CAR-T cells |
CN116655805B (en) * | 2023-05-31 | 2024-03-08 | 四川大学华西医院 | Novel CAR-T cell targeting HER2 positive tumor, preparation method and application |
CN116789859B (en) * | 2023-06-29 | 2024-02-23 | 徐州医科大学 | Target cell for evaluating drug effect of BCMA targeted CAR-T cell and application thereof |
CN116949099B (en) * | 2023-07-12 | 2024-04-02 | 山东大学第二医院 | Parallel chimeric antigen receptor T cell targeting CD38 and CS1 antigens and preparation method and application thereof |
CN117024594A (en) * | 2023-09-21 | 2023-11-10 | 武汉波睿达生物科技有限公司 | anti-CD 20 nano antibody and application thereof |
Family Cites Families (188)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US30985A (en) | 1860-12-18 | Thomas l | ||
FR901228A (en) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Ring gap magnet system |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
DE68925971T2 (en) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
KR0184860B1 (en) | 1988-11-11 | 1999-04-01 | 메디칼 리써어치 카운실 | Single domain ligands receptors comprising said ligands methods for their production and use of said ligands |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69120146T2 (en) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | GENERATION OF XENOGENIC ANTIBODIES |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (en) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES. |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
ES2113940T3 (en) | 1990-12-03 | 1998-05-16 | Genentech Inc | ENRICHMENT METHOD FOR PROTEIN VARIANTS WITH ALTERED UNION PROPERTIES. |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
ES2206447T3 (en) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | HUMANIZED ANTIBODY FOR HEREGULINE. |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
JPH07501451A (en) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | Multivalent antigen binding protein |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
ES2162823T5 (en) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | IMMUNOGLOBULINS DESPROVISTAS OF LIGHT CHAINS. |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
JPH08511420A (en) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | Body |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
ES2304786T3 (en) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
AU2660397A (en) | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
CA2258518C (en) | 1996-06-27 | 2011-11-22 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Recognition molecules interacting specifically with the active site or cleft of a target molecule |
DK1500329T3 (en) | 1996-12-03 | 2012-07-09 | Amgen Fremont Inc | Human antibodies that specifically bind TNF-alpha |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
DE69830315T2 (en) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | GALACTOSYLATED GLYCOPROTEIN CONTAINING COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
ATE419009T1 (en) | 1997-10-31 | 2009-01-15 | Genentech Inc | METHODS AND COMPOSITIONS CONSISTING OF GLYCOPROTEIN GLYCOFORMS |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
ATE531812T1 (en) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | HUMANIZATION OF RODENT ANTIBODIES |
EP1051493A2 (en) | 1998-01-26 | 2000-11-15 | Unilever Plc | Method for producing antibody fragments |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE375365T1 (en) | 1998-04-02 | 2007-10-15 | Genentech Inc | ANTIBODIES VARIANTS AND FRAGMENTS THEREOF |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
EP1135495A2 (en) | 1998-12-01 | 2001-09-26 | Genentech, Inc. | Secreted amd transmembrane polypeptides and nucleic acids encoding the same |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
ATE276359T1 (en) | 1999-01-19 | 2004-10-15 | Unilever Nv | METHOD FOR PRODUCING ANTIBODY FRAGMENTS |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
EP1171596A1 (en) | 1999-04-16 | 2002-01-16 | Celltech Therapeutics Limited | Synthetic transmembrane components |
EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | Process for producing polypeptide |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
WO2001062895A2 (en) | 2000-02-24 | 2001-08-30 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
ES2528794T3 (en) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Multivalent antibodies and uses thereof |
AU2001268855A1 (en) | 2000-05-26 | 2001-12-03 | National Research Council Of Canada | Single-domain antigen-binding antibody fragments derived from llama antibodies |
CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3523245B1 (en) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | Transgenic chromosome-introduced rodents for the production of human antibodies |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
DK1419179T3 (en) | 2001-08-10 | 2010-06-21 | Univ Aberdeen | Antigen binding domains from fish |
WO2003025020A1 (en) | 2001-09-13 | 2003-03-27 | Institute For Antibodies Co., Ltd. | Method of constructing camel antibody library |
JP2005289809A (en) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | Mutant heavy-chain antibody |
ES2326964T3 (en) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | GLICOPROTEIN COMPOSITIONS. |
US20030180296A1 (en) * | 2001-12-20 | 2003-09-25 | Theodora Salcedo | Antibodies that immunospecifically bind to trail receptors |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
ATE503829T1 (en) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP-FUCOSE TRANSPORT |
CA2481837A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
DE60332957D1 (en) | 2002-12-16 | 2010-07-22 | Genentech Inc | IMMUNOGLOBULIN VARIANTS AND ITS USES |
AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
EA036531B1 (en) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Type ii anti-cd20 humanized antibody (variants), pharmaceutical composition comprising these antibody variants, and use thereof |
KR101520209B1 (en) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | Monomethylvaline compounds capable of conjugation to ligands |
JPWO2005053742A1 (en) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | Medicament containing antibody composition |
MXPA06011199A (en) | 2004-03-31 | 2007-04-16 | Genentech Inc | Humanized anti-tgf-beta antibodies. |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
WO2005118788A2 (en) | 2004-05-27 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
EP1864998B2 (en) | 2004-07-22 | 2022-06-22 | Erasmus University Medical Center Rotterdam | Binding molecules |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
TWI380996B (en) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | Anti-ox40l antibodies |
EP1791565B1 (en) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
ES2577292T3 (en) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Binding polypeptides with diversified VH / VL hypervariable sequences and consensus |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
JP5184374B2 (en) | 2006-01-25 | 2013-04-17 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | Allele exclusion |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
US20100166734A1 (en) | 2006-12-20 | 2010-07-01 | Edward Dolk | Oral delivery of polypeptides |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (en) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | Liquid crystal panel drive device and its drive method |
CN101820911B (en) * | 2007-06-12 | 2015-05-06 | Ac免疫有限公司 | Humanized antibodies to amyloid beta |
EP2650311A3 (en) | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
PT2235064E (en) | 2008-01-07 | 2016-03-01 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
CN101550416B (en) * | 2008-03-18 | 2012-01-25 | 陈志南 | Humanized monoantibody Hu-ScFv18 light and heavy chain variable region gene and coding polypeptide thereof and application thereof |
US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
PT2954779T (en) | 2009-12-10 | 2019-05-29 | Regeneron Pharma | Mice that make heavy chain antibodies |
DK2580243T3 (en) * | 2010-06-09 | 2020-01-13 | Genmab As | ANTIBODIES AGAINST HUMAN CD38 |
KR20130100118A (en) | 2010-08-03 | 2013-09-09 | 아비에 인코포레이티드 | Dual variable domain immunoglobulins and uses therof |
CN113337402A (en) | 2011-10-17 | 2021-09-03 | 麻省理工学院 | Intracellular delivery |
TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
ES2774160T3 (en) * | 2012-02-13 | 2020-07-17 | Seattle Childrens Hospital D/B/A Seattle Childrens Res Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
JP2015509716A (en) * | 2012-02-22 | 2015-04-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Use of CD2 signaling domains in second generation chimeric antigen receptors |
CA2869562C (en) | 2012-04-11 | 2023-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
MX2015000426A (en) | 2012-07-13 | 2015-07-14 | Univ Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody. |
WO2014055442A2 (en) * | 2012-10-01 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting stromal cells for the treatment of cancer |
US9243058B2 (en) * | 2012-12-07 | 2016-01-26 | Amgen, Inc. | BCMA antigen binding proteins |
TW201425336A (en) | 2012-12-07 | 2014-07-01 | Amgen Inc | BCMA antigen binding proteins |
JP6636803B2 (en) * | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Method for selection of antibodies to BCMA |
CN104045713B (en) * | 2013-03-13 | 2019-02-12 | 江苏诺迈博生物医药科技有限公司 | The monoclonal antibody of anti-Blys a kind of and pharmaceutical composition containing the antibody |
TWI654206B (en) * | 2013-03-16 | 2019-03-21 | 諾華公司 | Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor |
AU2014248119B2 (en) * | 2013-04-03 | 2019-06-20 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted T-cells derived from pluripotent stem cells |
GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
WO2015120187A1 (en) | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
SG11201607203XA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | Non-human animals that make single domain binding proteins |
CN106687483B (en) | 2014-07-21 | 2020-12-04 | 诺华股份有限公司 | Treatment of cancer using humanized anti-BCMA chimeric antigen receptors |
JP6706244B2 (en) | 2014-07-24 | 2020-06-03 | ブルーバード バイオ, インコーポレイテッド | BCMA chimeric antigen receptor |
PE20170263A1 (en) * | 2014-08-04 | 2017-03-30 | Hoffmann La Roche | T-CELL ACTIVATING ANTIGEN-BINDING BI-SPECIFIC MOLECULES |
EP3029067A1 (en) | 2014-12-01 | 2016-06-08 | Deutsches Krebsforschungszentrum | Use of blocking-reagents for reducing unspecific T cell-activation |
SI3628687T1 (en) * | 2014-12-12 | 2021-12-31 | 2Seventy Bio, Inc. | Bcma chimeric antigen receptors |
US10961509B2 (en) | 2015-07-20 | 2021-03-30 | Angiocrine Bioscience, Inc. | Engineered endothelial cells expressing an ETS transcription factor |
CN105384825B (en) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
CN105777911B (en) | 2016-04-12 | 2019-07-02 | 上海优卡迪生物医药科技有限公司 | Anti- BCMA Chimeric antigen receptor, encoding gene, recombinant expression carrier and its construction method and application |
CN108395481B (en) | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | Construction of CD 20-targeted CAR and activity identification of engineered T cell thereof |
AU2018255926B9 (en) | 2017-04-19 | 2023-10-19 | Allogene Therapeutics, Inc. | Improved T cell compositions and methods |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | Chimeric antibody immune effctor cell engagers and methods of use thereof |
CN109306014B (en) | 2017-07-27 | 2022-04-12 | 上海细胞治疗研究院 | Intercortin-targeted chimeric antigen receptor modified T cell and application thereof |
WO2019133969A2 (en) | 2017-12-29 | 2019-07-04 | Memorial Sloan-Kettering Cancer Center | Enhanced chimeric antigen receptors and uses thereof |
US20210023170A1 (en) | 2018-02-12 | 2021-01-28 | University Of Florida Research Foundation, Incorporated | Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a |
AU2020339559A1 (en) | 2019-08-28 | 2022-04-14 | Nanjing Legend Biotech Co., Ltd. | Engineered T cells and methods of producing thereof |
BR112022011666A2 (en) | 2019-12-16 | 2022-12-20 | Nanjing Legend Biotech Co Ltd | CHIMERIC ANTIGEN RECEPTOR, ISOLATED NUCLEIC ACID, VECTOR, IMMUNE CELL, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OF A DISEASE, ANTIBODY |
-
2015
- 2015-11-02 CN CN201510733585.2A patent/CN105384825B/en active Active
-
2016
- 2016-08-10 UA UAA201802367A patent/UA125818C2/en unknown
- 2016-08-10 BR BR112018002844-4A patent/BR112018002844A2/en active Search and Examination
- 2016-08-10 EP EP22168161.2A patent/EP4063397A1/en active Pending
- 2016-08-10 EP EP16834662.5A patent/EP3334765A4/en active Pending
- 2016-08-10 CN CN201680047777.0A patent/CN109311999A/en active Pending
- 2016-08-10 CA CA2994579A patent/CA2994579C/en active Active
- 2016-08-10 SG SG10201913485QA patent/SG10201913485QA/en unknown
- 2016-08-10 WO PCT/CN2016/094408 patent/WO2017025038A1/en active Application Filing
- 2016-08-10 IL IL257297A patent/IL257297B/en unknown
- 2016-08-10 CR CR20180153A patent/CR20180153A/en unknown
- 2016-08-10 CR CR20210225A patent/CR20210225A/en unknown
- 2016-08-10 IL IL294683A patent/IL294683A/en unknown
- 2016-08-10 AU AU2016305075A patent/AU2016305075B2/en active Active
- 2016-08-10 US US15/751,609 patent/US10934363B2/en active Active
- 2016-08-10 KR KR1020187006996A patent/KR20180035918A/en not_active Application Discontinuation
- 2016-08-10 JP JP2018526984A patent/JP6859347B2/en active Active
- 2016-08-10 MX MX2018001739A patent/MX2018001739A/en unknown
- 2016-08-10 MY MYPI2018000199A patent/MY188362A/en unknown
- 2016-08-10 EA EA201890302A patent/EA201890302A1/en unknown
-
2017
- 2017-08-10 EP EP21166662.3A patent/EP3896091B1/en active Active
- 2017-08-10 KR KR1020237009392A patent/KR20230052294A/en active Application Filing
- 2017-08-10 MX MX2019001294A patent/MX2019001294A/en unknown
- 2017-08-10 KR KR1020247002596A patent/KR20240017408A/en active Application Filing
- 2017-08-10 UA UAA201901062A patent/UA126441C2/en unknown
- 2017-08-10 EP EP23199446.8A patent/EP4282877A3/en active Pending
- 2017-08-10 SG SG11201900635QA patent/SG11201900635QA/en unknown
- 2017-08-10 CA CA3189388A patent/CA3189388A1/en active Pending
- 2017-08-10 PT PT211666623T patent/PT3896091T/en unknown
- 2017-08-10 EA EA201990208A patent/EA201990208A1/en unknown
- 2017-08-10 HR HRP20231542TT patent/HRP20231542T1/en unknown
- 2017-08-10 FI FIEP21166662.3T patent/FI3896091T3/en active
- 2017-08-10 SI SI201731453T patent/SI3896091T1/en unknown
- 2017-08-10 AU AU2017311089A patent/AU2017311089B2/en active Active
- 2017-08-10 CN CN201780031233.XA patent/CN109153731B/en active Active
- 2017-08-10 CA CA3019453A patent/CA3019453C/en active Active
- 2017-08-10 CN CN202110529749.5A patent/CN113185616B/en active Active
- 2017-08-10 CN CN202110530320.8A patent/CN113234173B/en active Active
- 2017-08-10 NZ NZ750366A patent/NZ750366A/en unknown
- 2017-08-10 EP EP17838777.5A patent/EP3475307A4/en not_active Withdrawn
- 2017-08-10 CR CR20190050A patent/CR20190050A/en unknown
- 2017-08-10 RS RS20231139A patent/RS64925B1/en unknown
- 2017-08-10 CN CN202410006229.XA patent/CN117756941A/en active Pending
- 2017-08-10 BR BR112019002687-8A patent/BR112019002687A2/en unknown
- 2017-08-10 KR KR1020197001835A patent/KR102512934B1/en active IP Right Grant
- 2017-08-10 KR KR1020247002595A patent/KR20240014108A/en active Application Filing
- 2017-08-10 WO PCT/CN2017/096938 patent/WO2018028647A1/en active Application Filing
- 2017-08-10 US US16/303,587 patent/US11535677B2/en active Active
- 2017-08-10 HU HUE21166662A patent/HUE064534T2/en unknown
- 2017-08-10 EP EP23199692.7A patent/EP4282878A3/en active Pending
- 2017-08-10 CN CN202110529747.6A patent/CN113185615A/en active Pending
- 2017-08-10 CN CN202110530335.4A patent/CN113234174B/en active Active
- 2017-08-10 DK DK21166662.3T patent/DK3896091T3/en active
- 2017-08-10 JP JP2019506627A patent/JP6851461B2/en active Active
- 2017-08-10 CR CR20210042A patent/CR20210042A/en unknown
- 2017-08-10 LT LTEP21166662.3T patent/LT3896091T/en unknown
- 2017-08-10 MY MYPI2019000175A patent/MY192392A/en unknown
-
2018
- 2018-02-02 ZA ZA2018/00703A patent/ZA201800703B/en unknown
- 2018-02-09 CL CL2018000378A patent/CL2018000378A1/en unknown
- 2018-02-09 MX MX2022015823A patent/MX2022015823A/en unknown
- 2018-02-09 PH PH12018500295A patent/PH12018500295A1/en unknown
- 2018-02-11 SA SA518390904A patent/SA518390904B1/en unknown
- 2018-02-13 CO CONC2018/0001405A patent/CO2018001405A2/en unknown
- 2018-11-21 ZA ZA2018/07836A patent/ZA201807836B/en unknown
-
2019
- 2019-01-28 PH PH12019500193A patent/PH12019500193A1/en unknown
- 2019-01-30 CO CONC2019/0000946A patent/CO2019000946A2/en unknown
- 2019-02-03 IL IL264607A patent/IL264607A/en unknown
- 2019-02-07 CL CL2019000326A patent/CL2019000326A1/en unknown
-
2020
- 2020-01-08 AU AU2020200151A patent/AU2020200151C1/en active Active
-
2021
- 2021-01-22 AU AU2021200453A patent/AU2021200453C1/en active Active
- 2021-02-01 US US17/164,125 patent/US20210261675A1/en active Pending
- 2021-02-04 US US17/168,100 patent/US11186647B2/en active Active
- 2021-03-09 JP JP2021037374A patent/JP2021087455A/en active Pending
- 2021-03-25 JP JP2021052453A patent/JP7168173B2/en active Active
- 2021-06-23 CL CL2021001686A patent/CL2021001686A1/en unknown
- 2021-06-24 CL CL2021001706A patent/CL2021001706A1/en unknown
- 2021-11-03 US US17/518,123 patent/US20220127371A1/en active Pending
-
2022
- 2022-06-15 AU AU2022204180A patent/AU2022204180A1/en active Pending
- 2022-10-18 JP JP2022167222A patent/JP2022183283A/en active Pending
- 2022-12-27 JP JP2022210140A patent/JP2023024810A/en active Pending
-
2024
- 2024-02-02 JP JP2024014929A patent/JP2024032975A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL257297A (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
IL281819A (en) | Chimeric antigen receptors and methods of making | |
IL261941A (en) | Chimeric antigen and t cell receptors and methods of use | |
IL265800A (en) | Anti-lag-3 antibodies and methods of use thereof | |
HK1249405A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
HK1252857A1 (en) | Anti-cd3 antibodies and methods of use | |
IL255336A0 (en) | Chimeric antigen receptors and methods of their use | |
IL263626A (en) | Chimeric antigen receptors and methods for use | |
IL252295A0 (en) | Chimeric antigen receptors and methods of use thereof | |
ZA201608305B (en) | Monoclonal antibodies against her2 epitope and methods of use thereof | |
HK1259251A1 (en) | Humanized anti-c1s antibodies and methods of use thereof | |
IL252604B (en) | Chimeric antigen receptors and methods of use | |
ZA201703471B (en) | Anti-cldn chimeric antigen receptors and methods of use | |
IL265957A (en) | Anti-c1s antibodies and methods of use thereof | |
IL273538A (en) | Anti-trkb monoclonal antibodies and methods of use | |
AU2016222891A1 (en) | Anti-DLL3 chimeric antigen receptors and methods of use |